Background: A scoping review was conducted to examine the breadth of evidence related to
telehealth innovations being utilized in the treatment of opioid use disorder (OUD) with …

Telemedicine could improve access to medications for opioid use disorder (MOUD).
Telemedicine-delivered MOUD (TMOUD) has expanded substantially in response to the …

Background: Mobile health (mHealth) interventions have the potential to improve substance
use treatment engagement and outcomes, and to reduce risk behaviors among people who …

Background The potential for digital initiatives for opioid harm reduction is boundless.
Synthesized evidence on current interventions and their efficacy are emerging. This scoping …

Background Methadone is one of the most utilized treatments for opioid use disorder.
However, requirements for observing methadone dosing can impose barriers to patients and …

In recent decades, the United States has seen a substantial increase in the number of
people diagnosed with substance use disorder (SUD). Both SUDs and COVID-19 separately …

Background: Buprenorphine is a partial mu opioid agonist medication that has been shown
to decrease non-prescribed opioid use, cravings, and opioid related morbidity and mortality …

Background We conducted a pilot study to assess feasibility of using video directly-observed
therapy (DOT) for patients initiating buprenorphine to evaluate whether it is associated with …

Medication treatment for opioid use disorder (MOUD) is an effective evidence-based therapy
for decreasing opioid-related adverse outcomes. Effective strategies for retaining persons on …

Background: The coronavirus disease (COVID-19) pandemic has impacted patients
receiving methadone maintenance treatment (MMT) through opioid treatment programs …